Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors.

To study phenotype-genotype correlations, ErbB/Ras pathway tumors (transgenic for ErbB2, c-Neu, mutants of c-Neu, polyomavirus middle T antigene (PyV-mT), Ras, and bi-transgenic for ErbB2/Neu with ErbB3 and with progesterone receptor) from four different institutions were histopathologically compared with Wnt pathway tumors [transgenes Wnt1, Wnt10b, dominant-negative glycogen synthase kinase 3-beta, beta-Catenin, and spontaneous mutants of adenomatous polyposis coli gene (Apc)]. ErbB/Ras pathway tumors tend to form solid nodules consisting of poorly differentiated cells with abundant cytoplasm. ErbB/Ras pathway tumors also have scanty stroma and lack myoepithelial or squamous differentiation. In contrast, Wnt pathway tumors exhibit myoepithelial, acinar, or glandular differentiation, and, frequently, combinations of these. Squamous metaplasia is frequent and may include transdifferentiation to epidermal and pilar structures. Most Wnt pathway tumors form caricatures of elongated, branched ductules, and have well-developed stroma, inflammatory infiltrates, and pushing margins. Tumors transgenic for interacting genes such as protein kinase CK2alpha (casein kinase IIalpha), and the fibroblast growth factors (Fgf) Int2/Fgf3 or keratinocyte growth factor (Kgf/Fgf7) also have the Wnt pathway phenotype. Because the tumors from the ErbB/Ras and the Wnt pathway are so distinct and can be readily identified using routine hematoxylin and eosin sections, we suggest that pathway pathology is applicable in both basic and clinical cancer research.

[1]  Roger J. Daly,et al.  The Ras Signaling Pathway in Mammary Tumorigenesis and Metastasis , 2004, Journal of Mammary Gland Biology and Neoplasia.

[2]  C. MacArthur,et al.  Receptor Specificity of the Fibroblast Growth Factor Family* , 1996, The Journal of Biological Chemistry.

[3]  P. Lemaire,et al.  Phosphatidylinositol-3 kinase acts in parallel to the ERK MAP kinase in the FGF pathway during Xenopus mesoderm induction. , 2001, Development.

[4]  H. Neumann,et al.  Primäres Plattenepithelkarzinom der weiblichen Brustdrüse , 1998, Der Pathologe.

[5]  Elaine Fuchs,et al.  A common human skin tumour is caused by activating mutations in β-catenin , 1999, Nature Genetics.

[6]  P. Musiani,et al.  Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[7]  K. Sikora,et al.  Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Cardiff,et al.  The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting‡ , 2000, Oncogene.

[9]  A. Ljubimov,et al.  Myoepithelial and basement membrane antigens in benign and malignant human breast tumors , 1993, International journal of cancer.

[10]  R. Nagle,et al.  Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells. , 1986, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[11]  H. Varmus,et al.  A new nomenclature for int-1 and related genes: The Wnt gene family , 1991, Cell.

[12]  W. Birchmeier,et al.  New aspects of Wnt signaling pathways in higher vertebrates. , 2001, Current opinion in genetics & development.

[13]  R. Cardiff,et al.  Impact of progesterone receptor on cell-fate decisions during mammary gland development. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[14]  W. Muller,et al.  Mammary tumorigenesis and metastasis in transgenic mice. , 1994, Seminars in cancer biology.

[15]  G. Hortobagyi,et al.  Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Cardiff,et al.  Transgenic oncogene mice. Tumor phenotype predicts genotype. , 1991, The American journal of pathology.

[17]  M. Rudnicki,et al.  Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[18]  K. Sikora,et al.  Gene therapy for cancer using tumour-specific prodrug activation. , 1994, Gene therapy.

[19]  R. Cardiff,et al.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[20]  G. Peters,et al.  Potential oncogene product related to growth factors , 1987, Nature.

[21]  M. Lindstrom,et al.  ApcMin, a mutation in the murine Apc gene, predisposes to mammary carcinomas and focal alveolar hyperplasias. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Cardiff,et al.  Genetic background affects susceptibility to mammary hyperplasias and carcinomas in Apc(min)/+ mice. , 2001, Cancer research.

[23]  R. Cardiff,et al.  Insertion mutation of the int-1 and int-2 loci by mouse mammary tumor virus in premalignant and malignant neoplasms from the GR mouse strain , 1990, Journal of virology.

[24]  P. Leder,et al.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.

[25]  Jeremy Nathans,et al.  A new member of the frizzled family from Drosophila functions as a Wingless receptor , 1996, Nature.

[26]  M. Piccart.  Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  R. Cardiff,et al.  Activation of β-catenin signaling in differentiated mammary secretory cells induces transdifferentiation into epidermis and squamous metaplasias , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[28]  H. Varmus,et al.  Transgenes expressing the Wnt-1 and int-2 proto-oncogenes cooperate during mammary carcinogenesis in doubly transgenic mice , 1992, Molecular and cellular biology.

[29]  G. Shackleford,et al.  Preferential activation of Fgf8 by proviral insertion in mammary tumors of Wnt1 transgenic mice , 1997, Oncogene.

[30]  Y. Geng,et al.  Specific protection against breast cancers by cyclin D1 ablation , 2001, Nature.

[31]  R. van Nie,et al.  Biological and morphological characteristics of mammary tumors in GR mice. , 1971, Journal of the National Cancer Institute.

[32]  R. Cardiff,et al.  Activation of different Wnt/β-catenin signaling components in mammary epithelium induces transdifferentiation and the formation of pilar tumors , 2002, Oncogene.

[33]  R. Neve,et al.  The role of overexpressed HER2 in transformation. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  Hideki Yamamoto,et al.  Phosphorylation of Axin, a Wnt Signal Negative Regulator, by Glycogen Synthase Kinase-3β Regulates Its Stability* , 1999, The Journal of Biological Chemistry.

[35]  R. Cardiff,et al.  The Comparative Pathology of Human and Mouse Mammary Glands , 2004, Journal of Mammary Gland Biology and Neoplasia.

[36]  T. Tsukamoto,et al.  N-Ethyl-N-nitrosourea induces mammary cancers in the pituitary-isografted mouse which are histologically and genotypically distinct from those induced by N-methyl-N-nitrosourea. , 1996, Cancer letters.

[37]  H. Bazan,et al.  HGF- and KGF-induced activation of PI-3K/p70 s6 kinase pathway in corneal epithelial cells: its relevance in wound healing. , 2001, Experimental eye research.

[38]  P. Leder,et al.  Wnt-10b directs hypermorphic development and transformation in mammary glands of male and female mice , 1997, Oncogene.

[39]  D. Birnbaum,et al.  Mutations at BRCA1: the medullary breast carcinoma revisited. , 1998, Cancer research.

[40]  E. Fuchs,et al.  De Novo Hair Follicle Morphogenesis and Hair Tumors in Mice Expressing a Truncated β-Catenin in Skin , 1998, Cell.

[41]  R. Cardiff,et al.  Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.

[42]  Cori Bargmann,et al.  The neu oncogene encodes an epidermal growth factor receptor-related protein , 1986, Nature.

[43]  R. Cardiff,et al.  c-H-ras-1 expression in 7,12-dimethyl benzanthracene-induced Balb/c mouse mammary hyperplasias and their tumors. , 1988, Oncogene.

[44]  M. Neville,et al.  Introduction: Signaling in Mammary Development and Tumorigenesis , 2004, Journal of Mammary Gland Biology and Neoplasia.

[45]  P. Leder,et al.  β-catenin is a downstream effector of Wnt-mediated tumorigenesis in the mammary gland , 2001, Oncogene.

[46]  M. Stratton,et al.  The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  W. Muller,et al.  Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. , 1994, Molecular and cellular biology.

[48]  Z. Shao,et al.  The human myoepithelial cell is a natural tumor suppressor. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  D. Neal,et al.  Keratinocyte growth factor activates p38 MAPK to induce stress fibre formation in human prostate DU145 cells , 2001, Oncogene.

[50]  R. Nusse,et al.  Wnt signaling: a common theme in animal development. , 1997, Genes & development.

[51]  P. Leder,et al.  A Mouse Model for Breast Cancer Induced by Amplification and Overexpression of the neu Promoter and Transgene , 2000, Molecular medicine.

[52]  R. Cardiff,et al.  Activated neu Induces Rapid Tumor Progression (*) , 1996, The Journal of Biological Chemistry.

[53]  D M Barnes,et al.  Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance? , 1992, European journal of cancer.

[54]  P. Leder,et al.  Keratinocyte growth factor induces mammary and prostatic hyperplasia and mammary adenocarcinoma in transgenic mice. , 1996, Oncogene.

[55]  R. Cardiff,et al.  Mammary Disease Mice Model Premalignant Polyoma Middle-T Transgenic Updated Version , 2001 .

[56]  N. Bundred,et al.  Periductal inflammation and cigarette smoke. , 1994, Journal of the American College of Surgeons.

[57]  R. Cardiff,et al.  Protein kinase CK2 in mammary gland tumorigenesis , 2001, Oncogene.

[58]  F. Walsh,et al.  Epithelial (E‐) and placentae (P‐) cadherin cell adhesion molecule expression in breast carcinoma , 1993, The Journal of pathology.

[59]  John N. Hutchinson,et al.  Requirement for Both Shc and Phosphatidylinositol 3′ Kinase Signaling Pathways in Polyomavirus Middle T-Mediated Mammary Tumorigenesis , 1998, Molecular and Cellular Biology.

[60]  S. Barsky,et al.  The myoepithelial defense: a host defense against cancer. , 1997, Medical hypotheses.

[61]  M. Barcellos-Hoff,et al.  Transgenic mice carrying an imbalance in the native ratio of A to B forms of progesterone receptor exhibit developmental abnormalities in mammary glands. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[62]  T. Dale,et al.  Wnt Signaling and Mammary Tumorigenesis , 2004, Journal of Mammary Gland Biology and Neoplasia.

[63]  D. Seldin,et al.  Endogenous Protein Kinase CK2 Participates in Wnt Signaling in Mammary Epithelial Cells* , 2000, The Journal of Biological Chemistry.

[64]  T. Sun,et al.  Acidic and basic hair/nail ("hard") keratins: their colocalization in upper cortical and cuticle cells of the human hair follicle and their relationship to "soft" keratins , 1986, The Journal of cell biology.

[65]  P. Leder,et al.  The int‐2 gene product acts as an epithelial growth factor in transgenic mice. , 1990, The EMBO journal.

[66]  H. Lane,et al.  Myc and Mammary Cancer: Myc is a Downstream Effector of the ErbB2 Receptor Tyrosine Kinase , 2004, Journal of Mammary Gland Biology and Neoplasia.

[67]  P. Leder,et al.  Insertional mutagenesis identifies a member of the Wnt gene family as a candidate oncogene in the mammary epithelium of int-2/Fgf-3 transgenic mice. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[68]  W. Birchmeier,et al.  β-Catenin Controls Hair Follicle Morphogenesis and Stem Cell Differentiation in the Skin , 2001, Cell.